T he incredibly high quality of medical care that we are able to deliver to our patients today is built upon years of effort by physicians, physicianscientists, and other medical researchers. Yet, we find that we are often met with significant challenges in the clinic. There are still many poorly understood diseases, countless patients who are difficult to treat, and an array of complications that may arise from our well-intended therapies. Therefore, as medical practitioners, we all rely on ongoing medical research to continuously revolutionize medical knowledge. Furthermore, many of us have had the joy and satisfaction of finding ways to incorporate research, either formally or informally, into our medical careers. The September 2017 edition of the American Journal of Rhinology and Allergy showcases wonderful examples of how research efforts from all angles and at all levels can make an impact, and I am honored to serve as this month's guest editor. The untiring determination of the laboratory researchers featured here continues to provide much-needed insights into the underlying molecular causes of the diseases that we evaluate. It is clear that the laboratory-based mechanistic discoveries then set the stage for clinical investigators to capitalize on those advances, move them into medical practices, and provide the tools needed to make profound changes in treatment approaches.
We must always be guided by our patients' needs because this will lead us to where the holes in our current standards of care lie. For patients with sinus disease, anosmia is one of the symptoms that most severely impacts their quality of life, and it is also a symptom for which we have frustratingly little to offer by way of treatment options. Jiang et al. 1 showed that 3-month olfactory training with phenyl ethyl alcohol in patients with traumatic anosmia could significantly improve the phenyl ethyl alcohol odor threshold levels of their patients, which indicated that this could be recommended as a noninterventional option for these patients. Soyka et al. 2 studied patients who underwent skull base surgery for midline lesions by using a nasoseptal flap and found a significant decrease in olfactory function on the flap donor side. They proposed that it may be wise to have patients undergo a monorhinal smell test before surgery to prevent bilateral smell impairment in patients with preexisting single-sided hyposmia. Results from a basic science study by Li et al. 3 showed that soluble chitosan, a linear polysaccharide made from the chitin shells of crustaceans, can promote the differentiation of embryonic rat neuroepithelial cells. Indeed, because chitosan is already under investigation for other medicinal applications, including hemostasis, this study could well be an early investigation to suggest its use as an eventual therapy for anosmia.
Another study that provided fascinating scientific insight was by Ramakrishnan et al. 4 and explores the potential causative mechanisms that contribute to the epithelial barrier dysfunction seen in chronic rhinosinusitis. When looking at uncinate tissue specimens from patients with chronic rhinosinusitis and controls, they found that expression levels of two small proline-rich proteins were increased in the mucosal samples from the patients with chronic rhinosinusitis. Furthermore, pathway analysis indicated that these small proline-rich proteins changes could reflect an end-effect of tumor necrosis factor ␣ modulation. Their results both further our understanding of the mechanisms that underlie the mucosal inflammation seen in chronic rhinosinusitis and also suggest a possible future target for therapy.
Although we often think of medical research as a process that involves asking a question and then moving forward to answer it prospectively, three retrospective articles this month also remind us that there is plenty of valuable knowledge to be gained from retrospective review. Work by Møller et al. 5 highlighted the importance of further exploration into the pathologic role of upper respiratory tract bacteria in cystic fibrosis and primary ciliary dyskinesia, and the clear need for strict standardization of collection and analysis techniques. A review of dacryocystorhinostomy clinical research articles by Saniasiaya et al. 6 confirmed that endoscopic dacryocystorhinostomy should be considered as a safe therapeutic approach to treating children with recalcitrant excessive eye watering due to nasolacrimal duct obstruction. A review by Lobo et al., 7 of patients with sinonasal squamous cell carcinoma from two centers teaches us that, although squamous cell carcinoma with and squamous cell carcinoma without inverted papilloma have generally been considered to be two distinct diseases, their demographics and outcomes are quite similar.
Of equal weight are data gained from patient-reported outcomes. As sublingual immunotherapy (SLIT) becomes increasingly available in the United States, outcome comparisons with the now-traditional subcutaneous immunotherapy (SCIT) will be key to their appropriate application. Having gone through the experience of then weekly and now monthly injections required for SCIT with my own son, my initial bias was that the at-home and less-painful SLIT therapy would have been vastly preferred by most patients. In fact, Schwanke et al. 8 found, in a SCIT versus SLIT comparative study, that the change in Rhinoconjunctivitis Quality of Life Questionnaire score was statistically significant after 6 months and 1 year of treatment only in the participants who received SCIT. They suggested that the lack of significant improvement in the patients who received SLIT could have been due to difficulties in adhering to immunotherapy dosing schedules or to the small population size studied. In a study by Pecorari et al., 9 they examined differences in subjective and objective evaluations of changes in nasal airflow resistance after closed septorhinoplasty. Although the patient-reported symptom of nasal obstruction subjectively improved after surgery, the objective analysis of anterior active rhinomanometry did not show any statistically significant improvement, perhaps due to concurrent surgery on the nasal septum and the nasal valve.
Surgeons will appreciate the very comprehensive and practical guidance offered by Carney 10 in his How I Do It article in which he described a simple and safe way to perform a Draf III approach to the frontal sinus, with advice to help reduce operative time and minimize complications. Because my own area of research and clinical interest is largely focused on patients with aspirin-exacerbated respiratory disease (AERD), the triad of asthma, recurrent eosinophilic nasal polyps, and respiratory reactions to aspirin and nonsteroidal antiinflammatory drugs, I was delighted to find that this month's edition has two wonderful articles dedicated to this mysterious syndrome. Our understanding of immunoglobulin G4 (IgG4) related disease continues to evolve, and a case by Johal et al. 11 detailed a patient with coexistent IgG4-related sinus disease and AERD. Because the causative trigger is not known for either AERD or IgG4-related disease, this case of overlapping clinical syndromes pushes us to further consider the potential for overlapping mechanistic abnormalities that may underlie both diseases. Finally, White 12 lent his expertise regarding the epidemiology of AERD. Although much progress has been made in the field of AERD over the past decade and the enthusiasm that continues to drive further investigation is heartening, the article White 12 highlighted the critical need to increase awareness in the medical community to properly identify these patients.
As you settle in to read through this month's edition of the American Journal of Rhinology and Allergy, you will note that this series of articles covers a wide array of relevant disease topics and highlights the importance of expanding our research horizons to appreciate and learn from investigations at all levels, from the bench to the bedside and back! 
